According to our (Global Info Research) latest study, the global Prusagliflozin Tablets market size was valued at US$ 15.43 million in 2025 and is forecast to a readjusted size of US$ 82.64 million by 2032 with a CAGR of 5.0% during review period.
Prusagliptin is a novel, highly selective dipeptidyl peptidase‑4 inhibitor developed for the treatment of type 2 diabetes mellitus. It exerts its hypoglycemic effect by inhibiting DPP‑4 enzyme activity, thereby slowing the degradation of incretin hormones, enhancing glucose‑dependent insulin secretion, and suppressing glucagon release to regulate blood glucose levels in a physiological manner. With good oral bioavailability and favorable safety profile, it is administered orally as a single daily dose, either alone or in combination with other antidiabetic agents, to improve glycemic control in adult patients with type 2 diabetes.In 2025, global Prusogliptin production reached approximately 12–18 million bottles.
Prusogliptin operates within the competitive landscape of the global DPP-4 inhibitor market, where it carves out a distinct position as a novel, domestically developed therapeutic option. As a new entrant, it competes with several established agents, differentiating itself primarily through its optimized chemical structure, which confers high enzyme selectivity and a favorable pharmacokinetic profile. This positions it well for patients requiring multiple concomitant medications, as its low potential for drug-drug interactions enhances its clinical utility in complex comorbid populations. The market environment is characterized by a persistent, underlying demand driven by the rising global prevalence of type 2 diabetes, balanced against intense competition from both branded and generic alternatives, as well as the growing market share of newer drug classes like SGLT-2 inhibitors and GLP-1 receptor agonists. Despite these pressures, Prusogliptin benefits from strategic market positioning, leveraging its innovative profile and the expansion of the developer's product pipeline, including upcoming combination therapies, to secure a foothold and drive future growth within the evolving diabetes treatment ecosystem.
This report is a detailed and comprehensive analysis for global Prusagliflozin Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Prusagliflozin Tablets market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Prusagliflozin Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Prusagliflozin Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Prusagliflozin Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Prusagliflozin Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Prusagliflozin Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSPC Ouyi Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Prusagliflozin Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
7 Tablets Per Box
14 Tablets Per Box
Market segment by Combination Therapy
Combination With Metformin
Combination With Sglt-2 Inhibitors
Market segment by Sales Channels
Hospitals
Retail
Online
Market segment by Application
Treatment Of Type 2 Diabetes Mellitus
Improvement Of Glycemic Control
Adjuvant Therapy For Diabetic Complications
Others
Major players covered
CSPC Ouyi Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Prusagliflozin Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Prusagliflozin Tablets, with price, sales quantity, revenue, and global market share of Prusagliflozin Tablets from 2021 to 2026.
Chapter 3, the Prusagliflozin Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Prusagliflozin Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Prusagliflozin Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Prusagliflozin Tablets.
Chapter 14 and 15, to describe Prusagliflozin Tablets sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Prusagliflozin Tablets. Industry analysis & Market Report on Prusagliflozin Tablets is a syndicated market report, published as Global Prusagliflozin Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Prusagliflozin Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.